<DOC>
	<DOCNO>NCT02739100</DOCNO>
	<brief_summary>The main purpose determine pharmacokinetics ( PK ) Triferic iron administer via hemodialysate via two different intravenous route adult patient chronic kidney disease chronic hemodialysis ( CKD-5HD ) . It open-label , randomized single dose study .</brief_summary>
	<brief_title>Pharmacokinetics Preliminary Bioequivalence Triferic ( Ferric Pyrophosphate Citrate ) Administered Via Hemodialysate Intravenously Adult CKD-5HD Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Hemodialysis Solutions</mesh_term>
	<criteria>1 . The patient must able provide inform consent personally sign dated write informed consent document complete studyrelated procedure . 2 . The patient must undergo chronic hemodialysis chronic kidney disease least 3 month , expect remain hemodialysis able complete study . 3 . The patient must Screening ferritin level ≥100μg/L . 4 . The patient must Screening transferrin saturation ( TSAT ) 1545 % , inclusive . 5 . The patient must Screening total iron binding capacity ( TIBC ) ≥175 μg/dL . 6 . The patient must Screening hemoglobin ( Hgb ) concentration ≥9.5 g/dL . 7 . The patient must undergo hemodialysis least 3x/week . 8 . The patient must least minimally adequate measure dialysis dose define singlepool Kt/V ( dialyzer clearance urea multiply dialysis time , divide patient 's total body water ) ≥1.2 , KIDt/V ( online dialyzer clearance measure use ionic dialysance multiply dialysis time , divide patient 's total body water ) ≥1.2 measure within 28 day prior Baseline . 9 . Patient receiving , receive anticoagulation dialysis single dose unfractionated heparin low molecular weight heparin predialysis ; intermittent IV heparin bolus . 10 . The patient 's vascular access dialysis use study must stable function judgment Investigator . 11 . The patient must agree discontinue iron preparation ( oral IV ) 14 day prior Baseline . 12 . Female patient must pregnant breastfeed . They must amenorrheic past year surgically sterile agree become pregnant continuous use effective birth control method acceptable Investigator duration participation study . 1 . The patient RBC whole blood transfusion within 4 week prior Screening . 2 . The patient require continuous infusion heparin standard hemodialysis . 3 . The patient administration IV oral iron supplement ( include multivitamin iron ) within 14 day prior Baseline . 4 . The patient know active bleeding site AV fistula graft ( e.g. , gastrointestinal , hemorrhoidal , nasal , pulmonary , etc. ) . 5 . The patient live kidney donor identify livingdonor kidney transplant schedule occur study participation . ( Note : Patients await deceaseddonor transplant need exclude . ) 6 . The patient 's vascular access hemodialysis femoral catheter . 7 . The patient schedule surgical procedure study . 8 . The patient hospitalization within 4 week prior Screening ( except vascular access surgery ) , opinion Investigator , confers significant risk hospitalization course study . 9 . The patient history noncompliance dialysis regimen opinion Investigator 10 . The patient know ongoing inflammatory disorder ( CKD ) , systemic lupus erythematosus , rheumatoid arthritis , collagenvascular disease , currently require systemic antiinflammatory immunomodulatory therapy . 11 . The patient current febrile illness ( e.g. , oral temperature ≥100.4°F , 38.0°C ) . ( The patient may subsequently become eligible least 1 week resolution illness . ) 12 . The patient know bacterial , tuberculosis , fungal , viral , parasitic infection require antimicrobial therapy anticipate require antimicrobial therapy patient 's participation study . 13 . The patient know positive HIV , hepatitis B , hepatitis C ( viral testing require part protocol ) . 14 . The patient cirrhosis liver base histological criterion clinical criterion ( e.g. , presence ascites , esophageal varix , multiple spider nevus , history hepatic encephalopathy ) . 15 . The patient ALT and/or AST level consistently great twice upper limit normal time two month prior Baseline . 16 . The patient currently malignancy basal squamous cell skin cancer . 17 . The patient history drug alcohol abuse within 6 month prior Screening . 18 . The patient participate investigational drug study within 30 day prior Baseline . 19 . The patient condition , opinion Investigator , would make unlikely patient complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>bioequivalence</keyword>
</DOC>